Online citations, reference lists, and bibliographies.
← Back to Search

Association Of Malignant Mesothelioma And Asbestos Related Conditions With Ovarian Cancer: Shared Biomarkers And A Possible Etiological Link?

A. Rai, R. Flores
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
This paper references
10.1016/j.humpath.2009.02.013
Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions.
Y. Yuan (2009)
10.1097/JTO.0b013e3181f1903e
Frequency of Use and Predictors of Cancer-Directed Surgery in the Management of Malignant Pleural Mesothelioma in a Community-Based (Surveillance, Epidemiology, and End Results [SEER]) Population
R. Flores (2010)
10.1515/CCLM.2011.015
Evaluation of ovarian cancer biomarkers in subjects with benign asbestos-related pleural diseases
E. Park (2011)
10.1309/AJCPHSUJ15NEYMIP
A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases.
Y. Takeshima (2008)
10.1016/0046-8177(90)90050-F
A comparative immunohistochemical study of peritoneal and ovarian serous tumors, and mesotheliomas.
N. Khoury (1990)
10.1056/NEJM196503182721104
RELATION BETWEEN EXPOSURE TO ASBESTOS AND MESOTHELIOMA.
I. Selikoff (1965)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1002/DC.20771
MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells
B. Davidson (2007)
10.1002/cncr.22781
Generation and characterization of an ascitogenic mesothelin‐expressing tumor model
W. Cheng (2007)
10.1002/JSO.10270
Total abdominal colectomy, pelvic peritonectomy, and end‐ileostomy for the surgical palliation of mucinous peritoneal carcinomatosis from non‐gynecologic cancer
K. Stamou (2003)
10.1097/PAS.0b013e318033e7a8
h-Caldesmon, Calretinin, Estrogen Receptor, and Ber-EP4: A Useful Combination of Immunohistochemical Markers for Differentiating Epithelioid Peritoneal Mesothelioma From Serous Papillary Carcinoma of the Ovary
C. Comin (2007)
10.1158/1078-0432.CCR-06-1059
Gene Expression Signatures Differentiate Ovarian/Peritoneal Serous Carcinoma from Diffuse Malignant Peritoneal Mesothelioma
B. Davidson (2006)
10.1097/PAS.0b013e3181b6bde3
Tenascin-X is a Novel Diagnostic Marker of Malignant Mesothelioma
Y. Yuan (2009)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar